Contineum Therapeutics, Inc.
CTNM
$10.92
-$0.10-0.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -59.39M | -56.86M | -49.83M | -42.26M | -35.46M |
| Total Depreciation and Amortization | 313.00K | 294.00K | 275.00K | 258.00K | 220.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.96M | 7.87M | 6.30M | 3.82M | 2.30M |
| Change in Net Operating Assets | -2.36M | 2.25M | 3.98M | 5.33M | -406.00K |
| Cash from Operations | -52.47M | -46.44M | -39.28M | -32.85M | -33.35M |
| Capital Expenditure | -355.00K | -339.00K | -414.00K | -514.00K | -657.00K |
| Sale of Property, Plant, and Equipment | 0.00 | 20.00K | 20.00K | 20.00K | 20.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 34.71M | -10.45M | -63.16M | -69.25M | -50.68M |
| Cash from Investing | 34.35M | -10.77M | -63.56M | -69.74M | -51.32M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 0.00 |
| Issuance of Common Stock | 20.12M | 946.00K | 108.90M | 109.00M | 108.41M |
| Repurchase of Common Stock | -- | -- | -- | -- | -28.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | 0.00 |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -256.00K | -176.00K | 140.00K | 0.00 | -343.00K |
| Cash from Financing | 19.86M | 770.00K | 109.04M | 109.00M | 108.04M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.74M | -56.45M | 6.21M | 6.42M | 23.37M |